BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF
The pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license and option deal with ...
April 28, 2026 10:42 AM EDT DealsR&D BeOne joins the VEGF competition, but with a trispecific antibody Max Gelman Senior Editor The pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that